An Effectiveness and Safety Study of Ixazomib in Combination With Lenalidomide and Dexamethasone (IRD) in Participants With Multiple Myeloma (MM) Previously Receiving a Bortezomib-based Induction Regimen (US MM-6)

• Status: Active, not recruiting
• Trial end date: 2026-11-30

Summary

The purpose of this study is to determine the progression-free survival (PFS) at 2 years for MM participants previously receiving a bortezomib-based induction regimen to IRD.

• Phase: Phase 4

Details

• Lead Sponsor: Millennium Pharmaceuticals, Inc.
• Treatments: BB 1101; Bortezomib; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Glycine; Ixazomib; Lenalidomide; Thalidomide